Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Review of the pathology of benign and malignant tumors of the adrenal gland. Generally, all neoplasms of the adrenal gland may show endocrine activity with respective clinical syndromes. Such syndromes may give first clues for the important differential diagnosis between hyperplasia and neoplasia. There is no correlation between morphology and function of the various tumors. Cancers of the adrenal cortex are extremely rare. They occur at any age. At infancy, neoplasms of the adrenal cortex are almost always hormonally active and malignant. Adenomas and carcinomas of the adrenal cortex are discussed with special reference to the difficulty of differential diagnosis. The prognosis of carcinomas of the adrenal cortex is poor. The five years' survival rate amounts to 10--25%. The dignity of phaeochromocytoma can hardly be established by morphology alone. Most of them are benign. Metastases of these tumors are the only certain criterion of malignancy. Neuroblastoma metastasizes very early and--in case of bone marrow involvement--must be separated from lymphosarcoma, Ewing's sarcoma, and from undifferentiated leukemias. Cysts of the adrenal gland are very rare but they are important in the differential diagnosis of adrenal masses. Finally, tumors like myelolipoma are briefly discussed.
 ...
PMID:[Pathologic anatomy of adrenal tumors]. 741 71

Fifty dogs with pheochromocytoma were identified in a retrospective study of a 9-year period. For 24 of 50 dogs (48%), the tumor was an incidental finding during necropsy or surgery. Presenting signs were referrable to the nervous system in 7 of the 26 symptomatic dogs (27%); were referrable to the cardiopulmonary system in 7 of 26 dogs (27%); or were nonspecific, reflecting general systemic disease, in 17 of 26 dogs (65%). Abnormal clinical findings were highly varied but were also generally referrable to the cardiopulmonary and nervous systems. Six of 7 dogs (86%) evaluated were hypertensive (systolic range, 164 to 325 mm Hg; diastolic range, 110 to 198 mm Hg). Serum biochemical findings were nonspecific, although 11 of 39 dogs (28%) were hypercholesterolemic. Abdominal fluid samples were analyzed in 6 dogs; 3 were nondiagnostic, and 3 were interpreted as lymphosarcoma. The imaging studies that were of most value included abdominal radiographs (mass identified in 9 of 16 dogs [56%]), caudal vena caval angiography (tumor thrombus correctly diagnosed in 4 of 7 dogs [57%]), and abdominal ultrasonography (mass seen in 5 of 6 dogs [83%] and tumor thrombus seen in 3 of 5 dogs [60%]). Local tumor invasion was present in 26 of 50 dogs (52%), regional lymph node metastases in 6 of 50 dogs (12%), and distant metastases in 12 of 50 dogs (24%). Cause of death was tumor-related in 19 of 50 dogs (38%) and non-tumor related in 28 of 50 dogs (54%).
 ...
PMID:Pheochromocytoma in 50 dogs. 806 61

Out of 120 patients hospitalized with the diagnosis of metastases to the cervical lymph nodes and unknown primary location of the tumor, tumors were detected in 29 and lymphosarcoma in 10. In 24 (82.7%) patients the tumor was located in the upper respiratory tract and gastrointestinal tract. Malignant tumors of the naso- and stomatopharynx and vestibular part of the larynx most often metastasize into the lymph nodes. Radiotherapy was administered to all 81 patients with metastases and unknown location of the primary tumor and to 10 patients with lymphosarcoma of the cervical lymph nodes. The protocol of radiotherapy took account of the site of the metastases and probable primary tumor. A radical course provides cure in 15% of cases, as shown by follow-up of at least 2 years.
 ...
PMID:[Cancer metastases to the cervical lymph nodes in an unknown primary location of the tumor]. 981 84

The clinical and pathological findings of 28 cases (27 horses, 1 donkey) of equid sinonasal tumours examined at the Edinburgh Veterinary School are presented and include: seven cases of squamous cell carcinoma (SCC); five adenocarcinomas; three undifferentiated carcinomas; two adenomas; five fibro-osseous and bone tumours; and single cases of ameloblastoma, fibroma, fibrosarcoma, undifferentiated sarcoma, melanoma and lymphosarcoma. The median ages of animals affected with epithelial, and fibro-osseous/bone tumours were 14 and 4 years, respectively. Unilateral purulent or mucopurulent nasal discharge (81% of cases) and gross facial swellings (82% of cases) were the most common presenting signs with sinonasal tumours, with epistaxis recorded in just 23% of cases. Radiology and endoscopy were the most useful ancillary diagnostic techniques. The maxillary area was the most common site of tumour origin, and only three cases were definitively identified as originating in the nasal cavity. Four of the maxillary SCC lesions originated within the nasal cavities or maxillary sinuses, while two originated in the oral cavity. Fourteen of 15 carcinomas, but only two of the 13 remaining tumours, spread to other sites in the head. Only three cases of sinonasal tumour had lymph node metastases, and none had distant metastases. In the long term, surgical treatment with seven malignant tumours was unsuccessful (6 months median survival post-operatively), but was successful with four out of five benign tumours (no regrowth at a median of 4 years post-operatively).
 ...
PMID:Equine nasal and paranasal sinus tumours: part 2: a contribution of 28 case reports. 1032 34

Thirty-eight patients with stages II-III breast cancer after mastectomy, two patients with other tumors, and six patients with lymphosarcoma were examined. For detecting cancer metastases to the bone marrow, morphological analysis of puncture biopsy specimens was carried out in all patients with breast cancer; in patients with other diseases, puncture biopsy specimens of the tumor or lymph node were examined. Immunodiagnosis was carried out by the immunocytochemical method with detection of tumor antigens--monoclonal antibodies to cytokeratins, to breast cancer (ICO-25 and ICO-103), and to hemopoietic cells. All patients with breast cancer were divided into two groups: 1) 9 patients with cancer metastases to the bone marrow, confirmed by x-ray, histological, and morphological methods and 2) 29 patients without documented metastases to the bone marrow. Immunocytochemical methods detect isolated tumor cells in patients with suspected metastases to the bone marrow, lymph nodes, and other organs in cases when these cells are undetectable by routine morphological and histological methods.
 ...
PMID:[The immunodiagnosis of breast cancer metastases to the bone marrow]. 1054 64

Clinical symptoms in patients with primary orbital lymphosarcoma, generalized lymphosarcoma involving the orbital tissues, and metastatic tumors of the orbit of another origin are analyzed. The orbital process has bee studied in 158 patients. The most frequent symptoms were ptosis and exophthalmos. Decreased visual acuity, pain, sensation of swelling in the orbit caused by rapid tumor growth were characteristic of metastases to the tumor and orbital lymphosarcoma in total system's involvement. In case of an isolated involvement of the orbit, lymphosarcoma ran a more swift course than metastases to the orbit and orbital lymphomas in systemic involvement which ran an aggressive course. These data cannot serve as differential diagnostic signs. The decisive information is provided by morphological examination of a biopsy specimen.
 ...
PMID:[The characteristics of the clinical picture of lymphosarcoma and of a metastatic tumor of the orbit of another origin]. 1058 15

With the FDA approval of Rituximab in 1998 for the treatment of lymphoma, and Trastuzumab in 1999 for the treatment of breast cancer, monoclonal antibodies were officially added to the therapeutic armamentarium against malignancy. Most of the side effects associated with these agents are due to antigen-antibody interactions on specific cells and tissues. One of the most predictable side effects of these products is a constellation of various systemic effects including flu-like symptoms such as headache, fever, sweats, skin rash, shortness of breath, hypotension, nausea, and asthenia that occurs with the first infusion of such products. Rarely severe hypotension, bronchospasm, and hypoxia and even death have occurred. The pathophysiology of these reactions appears to be secondary to the release of cytokines as the antibodies bind do circulating antigen-expressing cells that are then removed in the reticuloendothelial system of the lungs, spleen and liver. In patients with large numbers of antigen-dense cells that have a high mitotic index, such as prolymphocytic leukemia, mantle cell lymphoma, or lymphosarcoma cell leukemia, there is a risk of true tumor lysis syndrome. One should be particularly cautious when treating patients with high numbers of circulating antigen-expressing cells in the setting of underlying cardiovascular or respiratory disease.
Cancer Metastasis Rev 1999
PMID:Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. 1085 89

The immunomodulatory and antimetastatic/antitumor activity of thymosin alpha(1) (Talpha(1)) was evaluated in BALB/c-mice. Daily subcutaneous application (7 consecutive days, 0.01-10 microg of Talpha(1)/injection per mouse) upregulated the number of thymocytes and peripheral blood cells in tumor bearing mice. To check the influence of Talpha(1) treatment on growth of experimental metastases, RAW H10 lymphosarcoma cells or L-1 sarcoma cells were intravenously injected into BALB/c-mice to establish liver or lung metastases. Local tumor growth was induced by subcutaneous injection of L-1 sarcoma cells. Talpha(1) was subcutaneously administered daily for 7 consecutive days starting 24 h after tumor cell challenge. Organ colonization, as well as local tumor growth, were investigated on day 14 after tumor cell inoculation, and demonstrated a statistically significant (P<0.05) reduction of experimental liver and lung metastases and local tumor growth for Talpha(1) treated mice.
 ...
PMID:Thymosin alpha(1) application augments immune response and down-regulates tumor weight and organ colonization in BALB/c-mice. 1097

The immunomodulatory and antimetastatic/antitumor activity of thymic humoral factor-gamma 2 (THF-gamma 2) was evaluated in BALB/c-mice. Daily subcutaneous applications (7 consecutive days, 20, 200 ng of THF-gamma 2 per injection/mouse) upregulated counts of thymocytes and peripheral blood cells in tumor bearing mice. To check the influence of THF-gamma 2 treatment on the growth of experimental metastases, RAW 117 H10 lymphosarcoma cells or L-1 sarcoma cells were intravenously inoculated into BALB/c-mice to establish liver or lung metastases, respectively. Local tumor growth was induced by subcutaneous injection of L-1 sarcoma cells. THF-gamma 2 was subcutaneously administered daily for 7 consecutive days starting 24 hrs after tumor cell challenge. Organ colonization as well as local tumor growth were investigated on day 14 after tumor cell inoculation and demonstrated a statistically significant (p < 0.05) reduction of experimental liver and lung metastases and local tumor growth for THF-gamma 2 treated mice.
 ...
PMID:Thymic humoral factor-gamma 2 augments immune cell response and exerts antitumor activity in murine model systems. 1120 90

The immunomodulatory and antimetastatic activity of standardized aqueous mistletoe extracts from plants grown on fir trees (ME-A) and pine trees (ME-P) were evaluated in BALB/c-mice. Regular subcutaneous (s.c.) and intraperitoneal (i.p.) applications (three times per week for 14 consecutive days; 5 and 50 microg per injection and mouse) upregulated thymus weight and peripheral blood leukocyte counts in tumor bearing mice. To check the influence of ME-A and ME-P treatment on growth of experimental metastases, RAW 117 H 10 lymphosarcoma cells and L-1 sarcoma cells were intravenously inoculated into BALB/c-mice to establish liver and lung colonization. ME-A and ME-P were regularly administered starting 24 h after tumor cell challenge. Organ colonization was investigated on day 14 after tumor cell inoculation and demonstrated statistically significant (P<0.05) reductions of experimental liver and lung metastases for ME-A and ME-P treated mice.
 ...
PMID:Application of standardized mistletoe extracts augment immune response and down regulates metastatic organ colonization in murine models. 1144 31


<< Previous 1 2 3 4 5 6 Next >>